NovaBay Pharmaceuticals, Inc.
NBY · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $3,374 | $3,105 | $2,936 |
| - Cash | $2,309 | $5,344 | $8,467 | $430 |
| + Debt | $405 | $1,042 | $1,125 | $1,672 |
| Enterprise Value | – | -$928 | -$4,237 | $4,178 |
| Revenue | $521 | $0 | $0 | $2,309 |
| % Growth | – | – | -100% | – |
| Gross Profit | $42 | $0 | $0 | $1,502 |
| % Margin | 8.1% | – | – | 65% |
| EBITDA | -$1,331 | -$1,926 | -$3,275 | -$1,195 |
| % Margin | -255.5% | – | – | -51.8% |
| Net Income | -$1,293 | -$1,922 | $7,670 | -$1,212 |
| % Margin | -248.2% | – | – | -52.5% |
| EPS Diluted | -0.22 | -0.33 | 1.42 | -0.27 |
| % Growth | 33.3% | -123.2% | 625.9% | – |
| Operating Cash Flow | -$1,800 | -$2,991 | -$1,324 | -$857 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$1,800 | -$2,991 | -$1,324 | -$857 |